Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred

Medicine

Volumn 81, Issue 2, 2002, Pages 101-121

  Whyte, Michael P ^a,b   Reinus, William R ^b   Podgornik, Michelle N ^a   Mills, Barbara G ^c  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c JOINT REPLACEMENT INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCITONIN; ETIDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; SALCATONIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BONE DEFORMATION; BONE DESTRUCTION; BONE DYSPLASIA; BONE REMODELING; CLINICAL ARTICLE; EXON; FAMILIAL DISEASE; FEMALE; FRACTURE; GENE DUPLICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MALE; METABOLIC BONE DISEASE; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; TRABECULAR BONE;

ADULT; AGED; BONE DISEASES, METABOLIC; CALCITONIN; DIPHOSPHONATES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; NORTHERN IRELAND; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOLYSIS; PEDIGREE; UNITED STATES;

EID: 0036124252     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200203000-00002     Document Type: Article

References (72)

1. Prevalence of pelvic Paget's disease of bone in the United States
2. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts
3. Idiopathic multicentric osteolysis: Report of two new cases and a review of the literature
4. Measurement of bone mineral in vivo: An improved method
5. Genetic linkage of Paget disease of the bone to chromosome 18q
6. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
7. The radiographic features of familial expansile osteolysis
8. Familial expansile osteolysis: A morphological, histomorphometric and serological study
9. Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption
10. Osteitis deformans (Paget)-or a tarda-type of a hereditary hyperphosphatasia
11. Osteolytic-expansive type of familial Paget's disease (osteitis deformans)
12. Conductive hearing loss caused by hereditary incus necrosis: A study of familial expansile osteolysis
13. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
14. Familial Paget's disease of bone: Nonlinkage to the PDB 1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree
15. Human calcitonin therapy: Efficacy in Paget's bone disease in patients with antibody resistance to heterologous calcitonins and in patients with lytic skeletal lesions
16. Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity
17. Role of RANK gene mutations in familial expansile osteolysis and familial and sporadic Paget's disease of bone
18. Familial Paget's disease of bone: Patterns of inheritance and frequency of linkage to chromosome 18q
19. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
20. Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis
21. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
22. Microfilaments associated with Paget's disease of bone: Comparison with nucleocapsids of measles virus and respiratory syncytial virus
23. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
24. Genetic linkage of familial expansile osteolysis to chromosome 18q
25. Familial expansile osteolysis: A genetic model of Paget's disease
26. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
27. Mechanism of aminobisphosphonate action: Characterization of alendronate inhibition of the isoprenoid pathway
28. Paget bone disease involving young adults in 3 generations of a Korean family
29. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone
30. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: Hereditary inclusion body myopathy, Paget disease of bone and frontotemporal dementia
31. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
32. Paget disease of bone: Mapping of two loci at 5q35-qter and 5q3
33. Variable disease severity associated with a Paget's disease predisposition gene
34. Identification of two previously undescribed patients with familial expansile osteolysis who have mutations in the TNFRSF11A signal peptide
35. Genetics of endocrine disease. The genetics of Paget's disease of the bone
36. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
37. Altered RANK mRNA transcript in CMO mice encodes a receptor with qualitative changes in the OPG ligand binding domain
38. Osteoprotegerin and osteoprotegerin-ligand balance: A new paradigm in bone metabolism providing new therapeutic targets
39. Dental abnormalities associated with familial expansile osteolysis: A clinical and radiographic study
40. Dental histology in familial expansile osteolysis
41. Frequency and characteristics of familial aggregation of Paget's disease of bone
42. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
43. Heterogeneity in Paget disease of the bone
44. Familial expansile osteolysis. A new dysplasia
45. An unusual familial disorder of bone: Response to calcitonin
46. On a form of chronic inflammation of bones (osteitis deformans)
47. Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease
48. Cell biology of Paget's Disease
49. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD 46 transgenic mice express characteristics of pagetic osteoclasts
50. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis: A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
51. RANKing the importance of measles virus in Paget's disease
52. The pharmacology of bisphosphonates and new insights into their mechanisms of action
53. Genetics of Paget's disease of bone
54. Update on viral etiology of Paget's disease of bone
55. Epidemiological aspects of Paget's disease: Family history and relationship to other medical conditions
56. Mutation screening of the TNFRSF11A gene encoding receptor activator of NFκB (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma
57. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival
58. Suggestion for a susceptibility locus for Paget's disease of bone on chromosome 18 and for genetic heterogeneity [abstract]
59. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: The factor is osteoprotegerin/osteoclastogenesis inhibitory factor
60. McCabe's disease: Hereditary expansile polyostotic osteolytic dysplasia
61. Familial expansile osteolysis
62. Arrest and healing of osteolytic Paget's bone disease with synthetic human calcitonin therapy: Radiographic documentation
63. Postmenopausal osteoporosis: A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients
64. Expansile skeletal hyperphosphatasia: A new familial metabolic bone disease
65. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF 11A encoding RANK and is allelic to familial expansile osteolysis
66. Evaluation of the role of RANK and OPG genes in Paget's disease of bone
67. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL